Review · United States
Abaloparatide
Reviewed on
Approval and product status
An FDA-approved product exists for defined osteoporosis populations
The study result belongs to the named prescription product, not every similar product or use. Tymlos is a product-specific prescription medicine. Trial findings do not validate unapproved PTHrP analogues or general performance use.
What was measured in people?
- Health results · Strong
- The ACTIVE phase 3 trial supports fracture-risk reduction in postmenopausal women with osteoporosis.
- Body changes · Strong
- Approved labeling characterizes PTH1-receptor activity, exposure, and bone-turnover effects.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
This prescription osteoporosis medicine has product-specific warnings and limits on use. No dose, injection, or performance guidance is provided.
Still unknown: The result does not establish that it is better than every osteoporosis medicine, improves healthy people, or heals every new injury better.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Products in this review
These are selected records, not every product or form.
Tymlos
- Ingredients and form
- Injection pen
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Osteoporosis uses in the high-fracture-risk populations defined in the product label.
Published label: 2025 label
Read the published Tymlos FDA label (PDF)What the research shows
The ACTIVE study compared abaloparatide with placebo or open-label teriparatide in postmenopausal women with osteoporosis. Abaloparatide reduced new spine and non-spine fractures versus placebo over 18 months.
Read all Abaloparatide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 3 sources
- TYMLOS (abaloparatide) prescribing information
U.S. Food and Drug Administration · Drug label · 2025
Source accessed
- Abaloparatide vs placebo on new vertebral fractures: ACTIVE
PubMed · JAMA · Randomized trial · 2016
Source accessed
- Drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed